Brief: Travere Therapeutics and CSL Vifor Announce Standard EU Approval of FILSPARI (sparsentan) for IgA Nephropathy
29/04/2025 13:23
April 29 (Reuters) - Travere Therapeutics Inc TVTX.O: TRAVERE THERAPEUTICS AND CSL VIFOR ANNOUNCE STANDARD EU APPROVAL OF FILSPARI® (SPARSENTAN) FOR IGA NEPHROPATHY Source text: ID:nBw9TV9j7a Further company coverage: TVTX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Travere Therapeutics
See all newsBrief: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Travere Therapeutics - Receives USPTO Notice Of Allowance For Filspari Patent In FSGS
Brief: Travere Therapeutics Announces Planned Chief Executive Officer Transition
Brief: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule